Inpatient therapy profile for coronary heart disease patients at Universitas Indonesia Hospital
DOI:
https://doi.org/10.34011/jmp2k.v36i1.3264Keywords:
coronary heart disease, inpatient, therapy profileAbstract
Background: Coronary heart disease (CHD) was the second-highest cause of death in Indonesia. West Java is one of the provinces with a high prevalence of heart disease in Indonesia.
Objective: This study aimed to determine the inpatient therapy profile for CHD patients at Universitas Indonesia Hospital (RSUI).
Methods: This study was a descriptive study using data from medical records of inpatients with CHD who were registered as BPJS Kesehatan participants at RSUI from January to September 2024.
Results: The results showed that 84 patients met the inclusion and exclusion criteria from a total study population of 208 patients, with the majority of patients being male (59,5%), aged <60 years (56,0%), and having a primary complaint of chest pain (79,8%). Based on laboratory characteristics, most patients had normal troponin T levels (86,9%), normal blood creatinine levels (54,8%), and random blood glucose levels <200 mg/dL (77,4%). The length of hospitalization was ≤5 days (82,1%) with improved clinical outcomes (97,6%). Most patients had ≥3 comorbidities (53,6%), with the most common comorbidities being HHD (38,1%), hypertension (35,7%), and CHF (33,3%). In addition, most patients received ≥5 drugs (97,6%), with the commonly used therapeutic profiles being platelet aggregation inhibitors (79,8%), HMG CoA reductase inhibitors (78,6%), organic nitrates (67,9%), selective beta-blocking agents (56,0%), and ACE inhibitors (45,2%).
Conclusion: The predominant therapeutic profile of CHD inpatients at RSUI included platelet aggregation inhibitors, HMG CoA reductase inhibitors, organic nitrates, selective beta-blocking agents, and ACE inhibitors.
References
[1] World Health Organization, “Cardiovascular Diseases.” WHO.int. https://www.who.int/health-topics/cardiovascular-diseases (accessed May. 23, 2025).
[2] World Health Organization, “The Top 10 Causes of Death.” WHO.int. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed May. 23, 2025).
[3] M. Naghavi et al., “Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and Territories and 811 Subnational Locations, 1990–2021: A Systematic Analysis for The Global Burden of Disease Study 2021,” The Lancet, vol. 403, no. 10440, pp. 2100–2132, May 2024, doi: 10.1016/S0140-6736(24)00367-2.
[4] IHME, “Health Profile for Indonesia.” HEALTHDATA.org. https://www.healthdata.org/research-analysis/health-by-location/profiles/indonesia (accessed May. 23, 2025).
[5] BKPK Kemenkes, Survei Kesehatan Indonesia (SKI) 2023. Jakarta: Kementerian Kesehatan Republik Indonesia, 2023.
[6] M. A. Chisholm-Burns, T. L. Schwinghammer, B. G. Wells, P. M. Malone, J. M. Kolesar, and J. T. Dipiro, Pharmacotherapy Principles & Practice, Fourth Edition. United States: McGraw-Hill Education, 2016.
[7] I. Oktaviani, F. Setiadi, and M. N. Oktovina, “Potensi Interaksi Obat pada Pasien Penyakit Jantung Koroner Akut di Rawat Inap Rumah Sakit Fartmawati Tahun 2023,” Jurnal Farmasi Klinik Best Practice, vol. 3, no. 2, pp. 56-70, 2024, doi: https://doi.org/10.58815/jfklin.v3i2.54.
[8] S. I. Kawengian, w I. Wiyono, and M. Mamarimbing, “Identifikasi Drug Related Problems (DRPs) pada Tahap Administration Pasien Penyakit Jantung Koroner di Instalasi Rawat Inap RSUP Prof. Dr. R. D. Kandou Manado,” Pharmacon, vol. 8, no. 1, pp. 1–10, Feb. 2019.
[9] V. A. Sagita, “Intervensi Apoteker Terhadap Masalah Terkait Obat Pasien Penyakit Jantung Koroner Rawat Inap di Rumah Sakit Umum Kabupaten Tangerang,” Universitas Indonesia, Depok, 2017.
[10] E. D. Armanda, L. Febriana, and A. D. Irawati, “Efektivitas Penggunaan Obat Kombinasi pada Pasien Jantung Koroner di Instalasi Rawat Jalan Rumah Sakit X Kota Madiun,” Jurnal Pengembangan Ilmu dan Parktik Kesehatan, vol. 3, no. 6, pp. 319-327, 2024.
[11] PERKI, Panduan Praktik Klinis (PPK) dan Clinical Pathway (CP) Penyakit Jantung dan Pembuluh Darah, Pertama. Jakarta: PERKI, 2016.
[12] M. Di Cesare et al., World Heart Report 2023: Confronting the World’s Number One Killer. Geneva, Switzerland: World Heart Federation, 2023.
[13] V. A. Sagita, A. Bahtiar, and R. Andrajati, “Evaluation of A Clinical Pharmacist Intervention on Clinical and Drug-Related Problems Among Coronary Heart Disease Inpatients: A Pre-Experimental Prospective Study at A General Hospital in Indonesia,” Sultan Qaboos University Medical Journal [SQUMJ], vol. 18, no. 1, p. 81, Apr. 2018, doi: 10.18295/squmj.2018.18.01.013.
[14] T. T. A. Truong et al., “Drug‐Related Problems in Prescribing for Coronary Artery Diseases in Vietnam: Cross‐Sectional Study,” Tropical Medicine & International Health, vol. 24, no. 11, pp. 1335–1340, Nov. 2019, doi: 10.1111/tmi.13310.
[15] Nurhidayah, E. Wahyudin, and H. Kasim, “Analisis Kombinasi Penggunaan Obat pada Pasien Jantung Koroner di Rumah Sakit Universitas Hasanuddin Makassar,” Majalah Farmasi dan Farmakologi, vol. 26, no. 1, pp. 15–18, 2022, doi: DOI: 10.20956/mff.v26i1.18754.
[16] X. Ye et al., “Association Between Healthy Lifestyle on Life Course and Multimorbidity in Adults: Results from Two National Prospective Cohort Studies,” BMC Public Health, vol. 24, no. 1, p. 2942, Oct. 2024, doi: 10.1186/s12889-024-20443-7.
[17] B. K. Alldredge et al., Koda-Kimble & Young’s, Applied Therapeutics, The Clinical Use of Drug, Tenth Edition. Philadelphia: Wolters Kluwer, 2013.
[18] Kepmenkes RI, Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sindroma Koroner Akut. Jakarta: Kepmenkes RI, 2019.
[19] Kepmenkes RI, Pedoman Nasional Pelayanan Kedokteran Tata Laksana Angina Pektoris Stabil. Jakarta: Kepmenkes RI, 2023.
[20] K. A. Zarkasi, N. Abdullah, N. A. Abdul Murad, N. Ahmad, and R. Jamal, “Genetic Factors for Coronary Heart Disease and Their Mechanisms: A Meta-Analysis and Comprehensive Review of Common Variants from Genome-Wide Association Studies,” Diagnostics, vol. 12, no. 10, p. 2561, Oct. 2022, doi: 10.3390/diagnostics12102561.
[21] M. M. Braun and W. A. Stevens, “Stable Coronary Artery Disease: Treatment,” Am Fam Physician, vol. 97, no. 6, 2018, Accessed: May 26, 2025. [Online]. Available: https://www.aafp.org/pubs/afp/issues/2018/0315/p376.html
[22] PERKI, Pedoman Tata Laksana Sindrom Koroner Akut, Ke-5. Jakarta: PERKI, 2024.
[23] PERKI, Panduan Tata Laksana Dislipidemia 2022. Jakarta: PERKI, 2022.
[24] J. DiPiro, G. Yee, S. Haines, T. Nolin, V. Ellingrod, and L. Posey, DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, Twelfth Edition. United States: McGraw-Hill, 2023.
[25] Y. Chen et al., “Heart Rate Control is Associated with Reduced Cardiovascular Events in Asian Patients with Coronary Artery Disease Treated with Bisoprolol (BISO-CAD): Results from A Multi-national, Real-World Experience,” Curr Med Res Opin, vol. 34, no. 2, pp. 217–225, Feb. 2018, doi: 10.1080/03007995.2017.1363729.
[26] M. Sobhy et al., “ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from The 2024 Egyptian Cardiology Expert Consensus in Collaboration with The CVREP Foundation,” Cardiol Ther, vol. 13, no. 4, pp. 707–736, Dec. 2024, doi: 10.1007/s40119-024-00381-6.
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2026 Khoirun Nisak, Retnosari Andrajati, Atika Wahyu Puspitasari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
